Beth Fand Incollingo

A trial (NCT01582672) that will pair a targeted treatment with a vaccine therapy for firstline treatment of renal cell carcinoma (RCC) is recruiting at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.

Although the presence of an EGFR mutation is a predictive marker for response to EGFR tyrosine kinase inhibitor therapy in patients with non-small cell lung cancer, the mutation is not a prognostic factor.